A drug discovery and development company dedicated to optimizing next-gen psychedelic medicines has unveiled a new technology that could forever alter the clinical psychedelic industry.
On Wednesday, Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) revealed that it had successfully developed an innovative, patent-pending intranasal formulation technology anticipated to provide enhanced central nervous system (CNS) penetration for first and future generations of psychedelic drugs.
Mindset claims to be an organization created to develop state-of-the-art medicinal assets that will assist with leveraging the breakthrough therapeutic potential of psychedelics. The outfit is currently engaged in a co-development agreement for its short-duration compounds (designated as Mindset Families 2 & 4) with the McQuade Center for Strategic Research and Development – a partner of the Japanese Otsuka Pharmaceuticals group of companies.
Additionally, the drug research professionals are currently refining a series of next-generation novel psychedelic compounds and developing a new inventive process to chemically synthesize psilocybin.
Today, we announce that we have developed a novel, patent-pending, intranasal platform formulation technology expected to deliver improved central nervous system (CNS) penetration of first & subsequent generations of #psychedelic medicines.$MSSTF $MSEThttps://t.co/p3A9TrSi3l
— Mindset Pharma Inc. (@MindsetPharma) June 29, 2022
Mindset’s new intranasal formulation utilizes its unique platform technology to alter the pharmacokinetic profile of active pharmaceutical elements, a uniform feature of multiple psychedelic drug candidates for the enterprise.
The proof of concept (PoC) or evidence of practicality and efficacy for Mindset’s new intranasal formulation has allegedly demonstrated superior CNS penetration compared to conventional formulations of 5-MeO-DMT administered in the past.
Mindset claims that its new unique formulation technology could potentially lessen peripheral side-effects, reduce required dose quantities and accelerate uptake and out-take from the brain. These clinical improvements will then theoretically enable more cost-efficient, safe and effective treatment.
“The intranasal formulation technology further enhances Mindset’s portfolio of complementary scientific assets. Now, the Company has a leading portfolio of next-generation NCEs, patent-pending processes to synthesize first-generation compounds efficiently and cost-effectively, and a novel intranasal delivery system to improve the overall pharmacokinetic properties of first- and second-generation psychedelic drug candidates,” said James Lanthier, CEO of Mindset Pharma.